SEC Form 4 · accession 0001209191-18-008205
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matt Abernethy
Officer — Chief Financial Officer
Period of report
Feb 5, 2018
Accepted (ET)
Feb 7, 2018 · 5:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Feb 5, 2018 | A | 12,250 | A | — | Mar 15, 2021 | Common Stock | 12,250 | 12,250 | D |
| Restricted Stock UnitF1,F3 | — | Feb 5, 2018 | A | 12,250 | A | — | Feb 5, 2020 | Common Stock | 12,250 | 12,250 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
- F2A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period.
- F3Performance Restricted Stock Units ("PRSU") will vest upon the date the Company has achieved both (1) obtaining positive pivotal clinical trial data for the treatment of Tourette syndrome with valbenazine and (2) FDA acceptance of a New Drug Application for the treatment of Tourette syndrome with valbenazine.